{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:26:56Z","timestamp":1791221216494,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,3,15]],"date-time":"2002-03-15T00:00:00Z","timestamp":1016150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Vincristine (VCR) is used widely in oncology practice, and regular dosing is commonly associated with the development of sensorimotor or autonomic neuropathies. However, the incidence of VCR\u2010related central nervous system (CNS) toxicity is comparatively low, suggesting that the blood\u2010brain barrier may limit drug penetration into the brain parenchyma. This study determined whether measurable concentrations of VCR could be detected in the cerebrospinal fluid (CSF), as a surrogate marker of brain parenchyma penetration, after bolus intravenous injection in children without primary CNS pathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors studied 17 pediatric patients ages 2.5\u201314.1 years (median, 6.8 years) with acute lymphoblastic leukemia or non\u2010Hodgkin lymphoma without evidence of leptomeningeal disease. Patients received VCR 1.5 mg\/m<jats:sup>2<\/jats:sup> by intravenous bolus injection followed at varying intervals by lumbar puncture for scheduled intrathecal methotrexate administration under general anesthesia. Paired VCR concentrations in both plasma and CSF were measured in each patient simultaneously at times ranging from 8 minutes to 146 minutes after the VCR injection. Three patients were studied twice. The paired samples were stored at \u221240 \u00b0C until analysis using a high performance liquid chromatography assay with a sensitivity of 0.1 \u03bcg\/L in CSF and 0.4 \u03bcg\/L in plasma.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Plasma VCR concentrations ranged from 2.2 \u03bcg\/L to 91.2 \u03bcg\/L. No measurable VCR concentrations were detected in the CSF samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Measurable concentrations of VCR in CSF are not achieved after the administration of standard intravenous bolus doses of VCR. The current observations are consistent with the relative rarity of VCR\u2010related CNS neurotoxicity compared with the commonly observed sensorimotor and autonomic neuropathies. These findings suggest that the penetration of VCR into the brain parenchyma of patients with a relatively intact blood\u2010brain barrier is low and that VCR may have a limited role in the CNS\u2010directed therapy of these patients. Cancer 2002;94:1815\u201320. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10397<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10397","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:42:44Z","timestamp":1030304564000},"page":"1815-1820","source":"Crossref","is-referenced-by-count":62,"title":["Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing"],"prefix":"10.1002","volume":"94","author":[{"given":"Stewart J.","family":"Kellie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Draga","family":"Barbaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siebold S. N.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,3,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(98)00023-7"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1994.tb00434.x"},{"key":"e_1_2_5_4_2","first-page":"1277","volume-title":"The pharmacological basis of therapeutics","author":"Calabresi P","year":"1985"},{"key":"e_1_2_5_5_2","first-page":"137","article-title":"Neuropsychiatric toxicity of vincristine sulphate therapy","volume":"4","author":"Laurens A","year":"1976","journal-title":"Clin Haematol"},{"key":"e_1_2_5_6_2","first-page":"277","volume-title":"Clinical pharmacology of anti\u2010neoplastic drugs","author":"Jackson DV","year":"1978"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01052723"},{"key":"e_1_2_5_8_2","first-page":"4478","article-title":"Interstitial pressure gradients in tissue\u2010isolated and subcutaneous tumors: implications for therapy","volume":"50","author":"Boucher Y","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005900908540"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004180050159"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-198007000-00007"},{"key":"e_1_2_5_12_2","first-page":"187","article-title":"Australian and New Zealand trials of acute lymphoblastic leukemia of childhood","volume":"5","author":"Waters K","year":"1998","journal-title":"Intl J Pediatr Hematol Oncol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199609)27:3<139::AID-MPO1>3.0.CO;2-F"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(91)80481-Q"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70027-3"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950240405"},{"key":"e_1_2_5_17_2","first-page":"1466","article-title":"Pharmacokinetics of vincristine in the cerebrospinal fluid of humans","volume":"41","author":"Jackson DV","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254016"},{"key":"e_1_2_5_19_2","first-page":"2212","article-title":"Mechanism of inhibition of cell proliferation by vinca alkaloids","volume":"51","author":"Jordan MA","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_20_2","first-page":"4346","article-title":"Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro","volume":"39","author":"Jackson DV","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0883-2897(91)90034-I"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282401"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1607"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1997.86.5.0747"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90085-8"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000120714"},{"key":"e_1_2_5_27_2","first-page":"733","article-title":"Clinical experience with vincristine (NSC\u201067574) in tumors of the central nervous system and other malignant diseases (Part 1)","volume":"52","author":"Smart CR","year":"1968","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.39.5.761","article-title":"Response of medulloblastoma to vincristine sulphate: a case report","volume":"39","author":"Lampkin B","year":"1967","journal-title":"Pediatrics"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1969.30.1.0042"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800530910"},{"key":"e_1_2_5_31_2","first-page":"639","article-title":"Chemotherapy of childhood medulloblastoma","volume":"130","author":"Crist WM","year":"1976","journal-title":"Am J Dis Child"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1976.45.2.0135"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90289-6"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.9.546"},{"key":"e_1_2_5_35_2","first-page":"379","article-title":"Pharmacokinetics of high\u2010dose etoposide (VP\u201016\u2010213) administered to cancer patients","volume":"44","author":"Handke KR","year":"1984","journal-title":"Cancer Res"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-198921000-00017"},{"key":"e_1_2_5_37_2","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose dependent plasma clearance of thiotepa","volume":"49","author":"Heideman RL","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_5_38_2","first-page":"1441","article-title":"Ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma","volume":"69","author":"DeGregorio MW","year":"1985","journal-title":"Cancer Treat Rep"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10397","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:31:32Z","timestamp":1760272292000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10397"}},"subtitle":["A surrogate marker of brain penetration"],"short-title":[],"issued":{"date-parts":[[2002,3,15]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,3,15]]}},"alternative-id":["10.1002\/cncr.10397"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10397","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,15]]}}}